Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.77 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.53 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3522283 | 1.00 | MAPK14 (0.77) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3525025 | 1.00 | MAPK14 (0.77) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3522340 | 0.91 | MAPK14 (0.81) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3522752 | 0.91 | MAPK14 (0.81) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL6057444 | 0.91 | MAPK14 (0.81) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3525524 | 0.90 | MAPK14 (0.83) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3521679 | 0.90 | MAPK14 (0.83) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3519218 | 0.90 | MAPK14 (0.78) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3524939 | 0.88 | MAPK14 (0.81) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3522903 | 0.88 | MAPK14 (0.83) | MAPK14MAPK11ROCK2MAPK12STRADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763353-A1 | COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X<sb>7</sb> RECEPTOR | Warner-Lambert Company LLC (US) | 2007-03-21 | — | — | EP | disclosed |
| US-20060018904-A1 | Combination therapies utilizing benzamide inhibitors of the P2X7 receptor | WARNER-LAMBERT COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2006003517-A1 | COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018904-A1 | Combination therapies utilizing benzamide inhibitors of the P2X7 receptor | CSF3R, CSF1R, IL1R1 | MAPK14 331/4885MAPK11 758/4885ROCK2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.